Semin intervent Radiol 2018; 35(02): 83-91
DOI: 10.1055/s-0038-1642622
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Novel Anticoagulant Treatment for Pulmonary Embolism with Direct Oral Anticoagulants Phase 3 Trials and Clinical Practice

Cécile Tromeur
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
Department of Internal Medicine and Chest Diseases, Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Hôpital de la Cavale Blanche, CHRU, Brest, France
Centre d'Investigation Clinique INSERM 1412, University of Brest, Brest, France
,
Liselotte M. van der Pol
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands
,
Albert T.A. Mairuhu
Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands
,
Christophe Leroyer
Department of Internal Medicine and Chest Diseases, Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Hôpital de la Cavale Blanche, CHRU, Brest, France
Centre d'Investigation Clinique INSERM 1412, University of Brest, Brest, France
,
Francis Couturaud
Department of Internal Medicine and Chest Diseases, Groupe d'Etude de la Thrombose de Bretagne Occidentale, Equipe d'Accueil 3878, Hôpital de la Cavale Blanche, CHRU, Brest, France
Centre d'Investigation Clinique INSERM 1412, University of Brest, Brest, France
,
Menno V. Huisman
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Frederikus A. Klok
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2018 (online)

Abstract

Anticoagulant therapy is the cornerstone of therapeutic management in acute venous thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis. Direct oral anticoagulants (DOACs) have become the standard of care because of their good safety profile and ease of use in clinical practice. Indeed, phase 3 randomized trials (AMPLIFY, EINSTEIN, RECOVER, and HOKUSAI studies) showed that DOACs provided a similar efficacy and a better safety than conventional treatment with parenteral heparin with overlapping loading dose of vitamin K antagonists in acute VTE therapeutic management. The results of published data from real-world registries confirm the safety and efficacy of DOACs demonstrated in the phase 3 trials.